scholarly journals High glycaemic variability is associated with progression of COVID-19

2021 ◽  
Author(s):  
Caroline Wei Shan Hoong ◽  
Xier Emily Yeo ◽  
Yi Lin ◽  
Say Tat Ooi ◽  
Ester Yeoh
Keyword(s):  
Glycaemic Variability

901-P: Effects of Dapagliflozin, Metformin, or Exercise on Glycaemic Variability and Mean Glucose Levels in Prediabetes: The PRE-D Trial

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 901-P
Author(s):  
KRISTINE FÆRCH ◽  
DORTE VISTISEN ◽  
MARTIN B. BLOND ◽  
LEA BRUHN NIELSEN ◽  
HANAN AMADID ◽  
...  
Keyword(s):  
Glycaemic Variability ◽  
Glucose Levels ◽  
Mean Glucose

scholarly journals Sleep quality and glycaemic variability in a real-life setting in adults with type 1 diabetes

Diabetologia ◽  
2021 ◽  
Author(s):  
Rachel Brandt ◽  
Minsun Park ◽  
Kristen Wroblewski ◽  
Lauretta Quinn ◽  
Esra Tasali ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Sleep Quality ◽  
Real Life ◽  
Glycaemic Variability ◽  
Real Life Setting

scholarly journals Continuous subcutaneous insulin infusion alters microRNA expression and glycaemic variability in children with type 1 diabetes

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Emma S. Scott ◽  
Andrzej S. Januszewski ◽  
Luke M. Carroll ◽  
Gregory R. Fulcher ◽  
Mugdha V. Joglekar ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Continuous Subcutaneous Insulin Infusion ◽  
Insulin Infusion ◽  
Diabetes Diagnosis ◽  
Subcutaneous Insulin ◽  
Glycaemic Variability ◽  
Altered Expression ◽  
C Peptide

AbstractTo determine whether continuous subcutaneous insulin infusion (CSII) vs. multiple daily injections (MDI) therapy from near-diagnosis of type 1 diabetes is associated with reduced glycaemic variability (GV) and altered microRNA (miRNAs) expression. Adolescents (74% male) within 3-months of diabetes diagnosis (n = 27) were randomized to CSII (n = 12) or MDI. HbA1c, 1-5-Anhydroglucitol (1,5-AG), high sensitivity C-peptide and a custom TaqMan qPCR panel of 52 miRNAs were measured at baseline and follow-up (median (LQ-UQ); 535 (519–563) days). There were no significant differences between groups in baseline or follow-up HbA1c or C-peptide, nor baseline miRNAs. Mean ± SD 1,5-AG improved with CSII vs. MDI (3.1 ± 4.1 vs. − 2.2 ± − 7.0 mg/ml respectively, P = 0.029). On follow-up 11 miRNAs associated with diabetes vascular complications had altered expression in CSII-users. Early CSII vs. MDI use is associated with lower GV and less adverse vascular-related miRNAs. Relationships with future complications are of interest.

Continuous glucose monitoring in acute stroke

2019 ◽  
Author(s):  
Laura Aponte-Becerra ◽  
Rodrigo Quispe ◽  
Laura Mendez-Pino ◽  
Vera Novak ◽  
Magdy Selim ◽  
...  
Keyword(s):  
Standard Deviation ◽  
Acute Stroke ◽  
Continuous Glucose Monitoring ◽  
Poor Prognosis ◽  
Glucose Monitoring ◽  
Mean Amplitude ◽  
P Value ◽  
Stroke Patients ◽  
Glycaemic Variability ◽  
Acute Brain Ischemia

"Hyperglycaemia upon admission is a pathophysiological response to acute brain ischemia that has been independently associated with high mortality rate and poor prognosis. Glycaemic variability (GV) has also shown association with poor clinical outcomes among stroke patients. GV is best assessed by continuous glucose monitoring (CGM), which enables consecutives glucose measurements every 5 minutes. This pilot study aimed: 1) To describe safety, feasibility and tolerability of CGM in the acute stroke setting; and 2) To compare CGM and conventional FS glucose-based monitoring regimen in terms of their relationship with GUA and the accuracy of hypoglycaemic episodes detection. Safety, feasibility and tolerability of CGM was excellent in our cohort of 23 patients with acute stroke (61% ischemic and 39% intracerebral haemorrhage) and there were no adverse events. CGM recorded ten hypoglycaemic episodes that were not detected by conventional FS monitoring. GUA was associated with coefficient of variation (CV) of CGM (p=0.03), CV of FS (p=0.01), standard deviation (SD) of CGM (p-value=0.01) and mean amplitude of glucose excursions (MAGE) (pvalue= 0.001)."

scholarly journals Breakfast replacement with a liquid formula improves glycaemic variability in patients with type 2 diabetes: a randomised clinical trial

2019 ◽  
Vol 121 (5) ◽  
pp. 560-566 ◽  
Author(s):  
Jiahui Peng ◽  
Jingyi Lu ◽  
Xiaojing Ma ◽  
Lingwen Ying ◽  
Wei Lu ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Blood Glucose ◽  
Glucose Monitoring ◽  
Mean Amplitude ◽  
Randomised Clinical Trial ◽  
Postprandial Blood Glucose ◽  
Glycaemic Variability ◽  
Intervention Measures ◽  
Before And After

AbstractThere is emerging evidence that glycaemic variability (GV) plays an important role in the development of diabetic complications. The current study aimed to compare the effects of lifestyle intervention (LI) with and without partial meal replacement (MR) on GV. A total of 123 patients with newly diagnosed and untreated type 2 diabetes (T2D) were randomised to receive either LI together with breakfast replacement with a liquid formula (LI+MR) (n 62) or LI alone (n 61) for 4 weeks and completed the study. Each participant was instructed to have three main meals per d and underwent 72-h continuous glucose monitoring (CGM) both before and after intervention. Measures of GV assessed by CGM included the incremental AUC of postprandial blood glucose (AUCpp), standard deviation of blood glucose (SDBG), glucose CV and mean amplitude of glycaemic excursions (MAGE). After a 4-week intervention, the improvements in systolic blood pressure (P=0·046) and time in range (P=0·033) were more pronounced in the LI+MR group than in the LI group. Furthermore, LI+MR caused significantly greater improvements in all GV metrics including SDBG (P=0·005), CV (P=0·002), MAGE (P=0·016) and AUCpp (P<0·001) than did LI. LI+MR (v. LI) was independently associated with improvements in GV after adjustment of covariates (all P<0·05). Our study showed that LI+MR led to significantly greater improvements in GV compared with LI, suggesting that LI+MR could be an effective treatment to alleviate glucose excursions.

scholarly journals Insulin glargine/lixisenatide fixed‐ratio combination improves glycaemic variability and control without increasing hypoglycaemia

2018 ◽  
Vol 21 (3) ◽  
pp. 726-731 ◽  
Author(s):  
Ronnie Aronson ◽  
Guillermo Umpierrez ◽  
William Stager ◽  
Boris Kovatchev
Keyword(s):  
Insulin Glargine ◽  
Fixed Ratio ◽  
Glycaemic Variability ◽  
And Control

Relationship between serum osteocalcin and glycaemic variability in Type 2 diabetes

2010 ◽  
Vol 38 (1) ◽  
pp. 50-54 ◽  
Author(s):  
Yu-Qian Bao ◽  
Mi Zhou ◽  
Jian Zhou ◽  
Wei Lu ◽  
Yun-Chao Gao ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Serum Osteocalcin ◽  
Glycaemic Variability

scholarly journals Roux-en-Y gastric bypass increases glycaemic variability and time in hypoglycaemia in patients with obesity and pre-diabetes/type 2 diabetes mellitus: a prospective cohort study

2020 ◽  
Author(s):  
Ibiyemi Ilesanmi ◽  
George Tharakan ◽  
Kleopatra Alexiadou ◽  
Preeshila Behary ◽  
Haya Alessimii ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Gastric Bypass ◽  
Diabetes Type 2 ◽  
Diabetes Type ◽  
Glucose Measurement ◽  
Glycaemic Variability ◽  
Study Objective ◽  
Post Surgery ◽  
Glucagon Like Peptide 1

<b>Objective:</b> Roux-en-Y gastric bypass (RYGB) is an established treatment for type 2 diabetes. The study objective was to establish RYGB’s effects on glycaemic variability (GV) and hypoglycaemia. <p><b>Research Design and Methods:</b> Prospective observational study of 10 participants with pre-diabetes/Type 2 diabetes undergoing RYGB, studied before surgery (Pre), 1 month (1m), 1 year (1y) and 2 years (2y) post-surgery with continuous glucose measurement (CGM). A mixed meal test (MMT) was performed at Pre, 1m and 1y. [ClinicalTrials.gov NCT01945840]</p> <p><b>Results:</b> After RYGB, mean CGM glucose fell (at 1m, 1y and 2y), and GV increased (at 1y and 2y). Fifty percent (5/10) of participants exhibited a percentage time in range <3.0 mmol/L [54 mg/dl] (%TIR<3.0) greater than the consensus target of 1% at 1y or 2y. Peak glucagon-like peptide-1 (GLP-1) and glucagon area-under-curve (AUC) during MMT were respectively positively and negatively associated with contemporaneous %TIR<3.0. </p> <b>Conclusions:</b> Patients undergoing RYGB are at risk of developing post-bariatric hypoglycaemia due to a combination of reduced mean glucose, increased GV and increased GLP-1 response.

Sign in / Sign up

Export Citation Format

Share Document